Published in Drug Metab Dispos on July 21, 2004
The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol (2011) 1.28
Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther (2012) 1.01
Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes. Planta Med (2010) 0.90
Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metab Dispos (2012) 0.89
Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol (2010) 0.89
Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. Toxicol Appl Pharmacol (2012) 0.88
A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos (2013) 0.85
The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug Metab Dispos (2014) 0.83
Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol (2006) 0.81
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models. Clin Pharmacokinet (2016) 0.79
The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis. Ann Transl Med (2014) 0.79
Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol (2006) 0.78
Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance. Drug Metab Dispos (2014) 0.77
Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates. J Pharmacol Exp Ther (2014) 0.76
Roles of Residues F206 and V367 in Human CYP2B6: Effects of Mutations on Androgen Hydroxylation, Mechanism-Based Inactivation, and Reversible Inhibition. Drug Metab Dispos (2016) 0.75
Labeled content of two furanocoumarins in dietary supplements correlates with neither actual content nor CYP3A inhibitory activity. J Pharm Biomed Anal (2014) 0.75
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 4.00
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 1.94
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest (2006) 1.75
Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther (2002) 1.68
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther (2005) 1.35
Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol (2005) 1.33
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics (2002) 1.30
Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther (2007) 1.22
Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology (2004) 1.21
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
The Environmental Polymorphisms Registry: a DNA resource to study genetic susceptibility loci. Hum Genet (2008) 1.18
Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci (2010) 1.14
A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr (2006) 1.12
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) (2003) 1.11
Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol Endocrinol Metab (2002) 1.10
Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology (2010) 1.08
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther (2006) 1.06
Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatology (2010) 1.03
A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. Toxicol Sci (2012) 1.02
In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn (2012) 1.02
Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos (2004) 1.01
Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int (2013) 1.00
An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther (2012) 0.98
Effects of a prolonged standardized diet on normalizing the human metabolome. Am J Clin Nutr (2009) 0.96
Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology (2010) 0.95
Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr (2008) 0.93
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos (2007) 0.92
Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther (2004) 0.92
Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf (2014) 0.91
Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. Biopharm Drug Dispos (2013) 0.90
Current challenges and controversies in drug-induced liver injury. Drug Saf (2012) 0.90
Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol (2007) 0.90
6'7'-Dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther (2004) 0.86
Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther (2002) 0.86
Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf (2014) 0.86
Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4? Br J Clin Pharmacol (2002) 0.84
Methodology to assess clinical liver safety data. Drug Saf (2014) 0.84
Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches. Front Physiol (2012) 0.84
Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther (2004) 0.84
CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Mol Interv (2005) 0.84
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br J Clin Pharmacol (2012) 0.83
Insight into hepatotoxicity: The troglitazone experience. Hepatology (2005) 0.82
Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics (2012) 0.81
Pharmacogenetics and clinical gastroenterology. Gastroenterology (2003) 0.81
Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J Pharmacol Exp Ther (2002) 0.80
Drug-induced liver injury network. Am J Gastroenterol (2008) 0.79
Toxicogenomics: transcription profiling for toxicology assessment. EXS (2009) 0.79
Role of cytochrome P450 phenotyping in cancer treatment. J Clin Oncol (2005) 0.78
Combination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in sandwich-cultured rat hepatocytes. Drug Metab Dispos (2012) 0.78
New insights into drug absorption: studies with sirolimus. Ther Drug Monit (2004) 0.78
Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. Drug Saf (2014) 0.78
Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. Pharmacogenet Genomics (2006) 0.77
The new revolution in toxicology: the good, the bad, and the ugly. Ann N Y Acad Sci (2013) 0.76
Effect of oxygen concentration on viability and metabolism in a fluidized-bed bioartificial liver using ³¹P and ¹³C NMR spectroscopy. Tissue Eng Part C Methods (2012) 0.76
Identification of Identical Transcript Changes in Liver and Whole Blood during Acetaminophen Toxicity. Front Genet (2012) 0.76
Did this drug cause my patient's hepatitis? Ann Intern Med (2003) 0.75
Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law. Drug Saf (2014) 0.75